CELL-EASY
Cell-Easy, a start-up based in Toulouse specialized in stem cell therapy, announces today the signature of an agreement with the University Hospital Centre in Toulouse, as well as securing the authorization to open a pharmaceutical manufacturing plant dedicated to the production of stem cells - a first in France. This follows the announcement made last December of raising 1M€ capital investment.
Thanks to its innovative mass scale stem cells manufacturing process, Cell Easy aims to develop regenerative medicine through therapeutic solutions based on Advanced Therapy Medicinal Products compatible with affordable access for millions of patients.
The start-up has now signed a first partnership with the University Hospital Center in Toulouse and will be producing Mesenchymal stem cells (or stromal cells) sourced from qualified fat tissue in accordance with good manufacturing practices. A first clinical trial is on its way to fight against Alzheimer disease.
« Our ambition is to industrialize our proprietary stem cell manufacturing process to make Cell Therapy accessible to the largest number possible of patients. The aim is to cut costs by ten and increase production capacity beyond 100 0000 doses /year. » explains Pierre Monsan, DG of Cell-Easy and Founder of Toulouse White Biotechnology (TWB).
« Today, stem cell-based treatments represent a major therapeutic hope. What has been set up here is very much the expression of the way the University Hospital Centre approaches the development of innovative technologies, therapies and organizations that support new therapies founded on cross fertilization of talent and expertise . » says Marc Penaud, Executive Manager of the University Hospital Center in Toulouse.
Furthermore, the French Medicines Agency, also gave Cell-Easy the authorization to open a pharmaceutical plant to manufacture stem cell batches at large scale, in accordance with GMP (Good Manufacturing Practices) standards. This authorization makes Cell-Easy the only private pharmaceutical organization able to manufacture stem cells in France on an industrial scale. This firmly puts Cell-Easy on the European stage.
Capital investment is being secured to finance the quick implementation of their strategy in France but also in Europe where patients’ needs are high.
Cell-Easy will now be able to manufacture stem cells batches for industrial partners and is one of the world’s precursors in cell therapy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results1.5.2025 22:24:00 CEST | Press release
The Company generated net sales of $45.0 million for the quarter and $158.4 million for the yearIncome before income taxes of $5.3 million for the quarter and $18.5 million for the yearBacklog of $138.1 million at January 31, 2025, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the fourth quarter and 2024 fiscal year ended January 31, 2025. “Sales for the fourth quarter and full year 2024 show moderate growth and were $45.0 million and $158.4 million, resulting in increases of $4.8 million and $7.7 million, compared to the prior year. Income before taxes was $5.3 million and $18.5 million in the fourth quarter and for the full year 2024, which increased by $2.1 million and $8.6 million, compared to the prior year. This significant increase was a result of our focus on higher margin products and services that contributed to improved margin performance. Net income after taxes and minority interest
IFF Declares Dividend for Second Quarter 20251.5.2025 22:15:00 CEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501776988/en/
Rimini Street Announces Fiscal First Quarter 2025 Financial and Operating Results1.5.2025 22:01:00 CEST | Press release
First Quarter Financial Highlights Include: Gross margin of 61.0% compared to 59.8% in the prior year Net Income of $3.4 million compared to $1.3 million in the prior year Billings of $79.4 million, up 7.2% year over year Adjusted EBITDA of $15.3 million compared to $10.7 million in the prior year Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501664008/en/ Select First Quarter 2025 Financial Results Revenue was $104.2 million for the 2025 first quarter, a decrease of 2.4% compared to $106.7 million for the same period last year. U.S. revenue was $50.1 million for the 2025 first quarter, a decrease of 6.9% compared to $53.8 million for the same per
Textron Aviation Calls on Cessna, Beechcraft and Hawker Owners to Transport Athletes to the 2026 Special Olympics USA Games1.5.2025 17:31:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. The company is calling on Cessna, Beechcraft and Hawker aircraft owners and operators to come together on Friday, June 19, 2026, and Saturday, June 27, 2026, to enable champions from all corners of the nation to travel to and from the host city, regardless of financial or logistical challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430812758/en/ Textron Aviation Inc. announced the coordination of the ninth Special Olympics Airlift, a monumental event aimed at transporting hundreds of athletes and coaches across country to the 2026 Special Olympics USA Games in Minnesota’s Twin Cities. (Photo credit: Textron Aviation) The Special Oly
Giovanni Brienza Appointed President of Frontline International1.5.2025 17:16:00 CEST | Press release
Longtime leader to guide day-to-day operations Frontline International, celebrating 25 years of innovation in commercial kitchen solutions, has appointed Giovanni Brienza as its new president. Founder John Palazzo will continue as CEO, focusing on strategic direction and long-term growth initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501026483/en/ Giovanni Brienza, Frontline International President Frontline is a USA-based manufacturer of systems used globally by foodservice operations for safer, more sustainable fat, oil, and grease (FOG) management. The company’s automated solutions increase kitchen safety. Brienza, who joined Frontline in 2004, brings 21 years of operational expertise and engineering insight to his new role. He has been a key architect behind many of Frontline’s most impactful innovations, from equipment and software systems to strategically expanding the company’s footprint into key inter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom